Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval To Begin Human Clinical Trials Of Sapu003, An Injectible Form Of Afinitor(R) (Everolimus) For Breast Cancer Treatment

2025-10-01 02:03:48

(MENAFN- Investor Brand Network)

Sapu Nano received approval from Australia's Human Research Ethics Committee (“HREC”) to start enrolling patients in clinical trials for Sapu003
Sapu003 uses Sapu Nano's Deciparticle(TM) technology to deliver more of the Everolimus drug into the bloodstream, which could be more effective than taking the drug in pill form
Sapu Nano is a part of a family of companies formed through GMP Biotechnology Limited, which itself is a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited

Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently received approval from the HREC in Australia to begin enrolling people in clinical trails of Sapu003 for the treatment of breast cancer.

Sapu003 is an injectible from of Affinitor(R) (Everolimus), which is an FDA-approved drug for treating different types of advanced cancer including breast cancer, kidney cancer, and affiliated...

About Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics is a biopharmaceutical company that develops therapeutics for cancer and other underserved diseases. The company has a portfolio of clinical-stage candidates and is focused on transforming outcomes for patients suffering from rare and/or difficult-to-treat conditions.

For more information, visit the company's website at .

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company's newsroom at ibn/OTLC

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers : (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ; (2) article and editorial syndication to 5,000+ outlets ; (3) enhanced press release enhancement to ensure maximum impact ; (4) social media distribution via IBN to millions of social media followers ; and (5) a full array of tailored corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: /Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by IBN

MENAFN01102025000224011066ID1110138086

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.